iShares Biotechnology ETF
277 hedge funds and large institutions have $3.24B invested in iShares Biotechnology ETF in 2013 Q4 according to their latest regulatory filings, with 53 funds opening new positions, 88 increasing their positions, 94 reducing their positions, and 26 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
277
Holders Change
+24
Holders Change %
+9.49%
% of All Funds
8.05%
Holding in Top 10
19
Holding in Top 10 Change
+7
Holding in Top 10 Change %
+58.33%
% of All Funds
0.55%
New
53
Increased
88
Reduced
94
Closed
26
Calls
$177M
Puts
$443M
Net Calls
-$266M
Net Calls Change
-$303M
Top Buyers
| 1 |
Goldman Sachs
New York
|
+$204M |
| 2 |
Citigroup
New York
|
+$172M |
| 3 |
Bank of Nova Scotia
Toronto,
Ontario, Canada
|
+$73.3M |
| 4 |
Bank of America
Charlotte,
North Carolina
|
+$52.5M |
| 5 |
Canada Life
Winnipeg,
Manitoba, Canada
|
+$23.8M |
Top Sellers
| 1 |
Allianz Asset Management
Munich,
Germany
|
-$115M |
| 2 |
DC
Davenport & Co
Richmond,
Virginia
|
-$50.4M |
| 3 |
Neuberger Berman Group
New York
|
-$33.3M |
| 4 |
Barclays
London,
United Kingdom
|
-$18.2M |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$10.2M |
